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Abstract
Objective. Damage in patients with systemic lupus erythematosus is irreversible change in organs due to disease
activity, concomitant disease or medication side-effects. It is measured using the Systemic Lupus International
Collaborative Clinics Damage Index (SDI) and is associated with increased mortality. Previous reports have suggested
associations between damage accrual and various ethnic, disease and treatment factors, but there is a dearth of long-
term follow-up data from large multi-ethnic cohorts. We describe a study of damage and mortality in 300 patients from
London, UK followed for up to 40 years.
Methods. We carried out retrospective analysis of medical records and SDI scores of 300 patients followed for up to
40 years (median 13.3 years). Characteristics of the groups who did and did not develop damage and those who died or
survived to the end of follow-up were compared using univariable and multivariable analysis. Kaplan-Meier analysis was
used to analyse factors affecting mortality and accrual of damage.
Results. Damage developed in 231/300 (77%) of patients. There was a linear accrual of damage over 40 years follow-
up. Factors associated with damage were African/Caribbean ethnicity, renal and cerebral involvement, early use of
high-dose corticosteroids or immunosuppressants, anti-RNP and antiphospholipid antibodies. Damage was strongly
associated with mortality. Of 87 patients who died, 93% had damage compared with 70% of survivors (P < 0.001).
Conclusion. Development of damage is strongly associated with increased mortality. We identified groups at increased
risk of developing damage, including those treated with high-dose steroids and immunosuppressants within the first two
years.
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Rheumatology key messages
. Long-term follow-up showed linear accrual of damage in 77% of patients with SLE.
. Development of damage in SLE patients was strongly associated with increased risk of death.
. Renal and cerebral involvement, early high-dose corticosteroids and immunosuppressants were associated with
increased damage.
Introduction
SLE is a chronic multi-system autoimmune disease that
can affect various organs or systems leading to a broad
spectrum of clinical manifestations. These manifestations
range from mild and transient to severe and life-threatening.
With the introduction of new forms of therapy including
immunosuppressive agents and biologics, there has
been a considerable improvement in the 5-year survival
rate of patients with SLE from 50% to over 90% [1].
Therefore, patients are living longer with the disease and
this longer life expectancy can be associated with devel-
opment of long-term chronic organ damage and disability
as a result of persistent disease activity and/or treatment
side effects [2]. There is a significant association between
the development of damage and mortality in patients
with SLE.
To assess chronic organ damage in SLE, the SLICC/
ACR damage index (SDI) has been used since 1996
[3, 4]. This index evaluates 12 organs/systems detecting
damage in patients regardless of its origin (caused by
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disease activity or by drug side effects). Each item
has to be present for at least 6 months, to differentiate
and avoid confusion between disease activity and
damage.
Previous cohort data found a higher mortality in patients
with SLE developing chronic damage within one year from
disease onset [5,6]; however, many of the previous longi-
tudinal studies quantified accrual of damage only at one
point during the disease course [7,8].
In a previous paper [9], we reported on SLICC-DI
scores in 350 patients from the lupus clinic at
University College Hospital London followed for a
median of 9 years. The specific aim of that analysis
was to assess the impact of factors such as disease
activity, therapy and serology recorded during a spe-
cific 12-month window after the first clinic visit upon
future development of damage. However, that limited
analysis did not assess serology and therapy over the
whole course of the disease and only 40% of the pa-
tients had developed any damage by the end of the
follow-up period.
Therefore, in the current paper, we carried out a more
comprehensive analysis of factors affecting develop-
ment of damage in 300 patients with SLE seen at
University College Hospital London, with follow-up ex-
tending up to 40 years and including data on serological
and treatment factors recorded over the whole disease
course.
Methods
Patients
The study cohort consisted of 300 patients attending the
Lupus Clinic of University College Hospital London, who
all fulfilled the 1997 revised criteria of the ACR for the
diagnosis of SLE [9]. Medical records of all the patients
were reviewed to identify demographic data, clinical mani-
festations of SLE and previous and current treatment.
Damage was assessed using the SDI. Only data obtained
as part of routine clinical management were included and
only pooled data with no patient identifiable information
are reported in this paper. Thus, research ethics approval
was not required.
Among the 300 SLE patients, we identified 231 (77%)
patients who had damage and compared their medical
records with those of the 69 patients who had never de-
veloped damage. By retrospective analysis of medical re-
cords, we obtained comprehensive information about
demographic, clinical, serological and treatment factors
in these two groups.
With reference to the treatment, use of early high-dose
steroids was defined as daily dose 55 mg prednisolone
started within the first two years after diagnosis. This cut-
off was chosen on the basis of data from the Hopkins
Lupus Cohort, Baltimore, USA showing significant in-
crease in damage at mean dose >6mg/day [10]. Any i.v.
methylprednisolone pulses were also counted as high
dose.
Statistical analysis
Demographic and clinical characteristics were compared
between groups of patients  damage vs no damage,
early damage (45 years) vs late damage, and those who
died vs those who survived: who developed damage and
those who did not, using a Pearson 2 for categorical vari-
ables or a Student’s t test for continuous variables [data
expressed as mean (S.D.)]. For non-continuous variables,
either a MannWhitney U test was performed or a loga-
rithmic transformation was made, and data expressed as
median and interquartile range (IQR). Multivariable logistic
regression analysis was performed to establish the rela-
tion of demographic, clinical and treatment factors.
Survival and damage-free survival from enrolment in the
clinic were assessed by the Kaplan Meier method.
The STATA for Windows statistical software package
(v.13.1) was used for all statistical analysis. Significance
was defined as P <0.05.
Results
Patients who develop damage are more likely to have
experienced renal or CNS involvement or to have taken
steroids/immunosuppressants than those with no
damage.
Table 1 shows a comparison of the 231 patients (77%
of the total cohort of 300 patients) who developed chronic
damage and the group of 69 patients who have not de-
veloped damage. These two groups did not differ in age,
sex or ethnicity.
Patients who developed damage were more likely to
have suffered from kidney involvement than those who
did not (42% vs 16%, P <0.001) and the same was true
of central nervous system involvement (30% vs 15%,
P =0.009). No other clinical features differed between
the damage and no damage groups. In terms of serology,
a history of ever having low complement or elevated anti-
dsDNA were both more common in the damage than the
non-damage group (46% vs 23%, P = 0.013; and 64% vs
48%, P =0.013, respectively). Among the antibodies to
extractable nuclear antigens, only the presence of positive
anti-RNP antibody was more frequent in the damage than
the no damage group (27.3% vs 13%, P =0.015). Positivity
for antiphospholipid antibodies (anti-cardiolipin and/or
anti-beta-2-glycoprotein I and/or lupus anticoagulant at
any time) was also more frequent in the damage group
(29% vs 11% P =0.044). There was no difference between
groups who were single-positive, double-positive or triple-
positive for these three antiphospholipid tests.
Patients in the damage group were more likely to have
ever been treated with steroids and various immunosup-
pressants (IS). Whereas 82.5% of the damage group
had ever been treated with steroids, this was only true
in 58.6% of the non-damage group (Pearson 2 = 13.83,
P< 0.001). Patients in the damage group were significantly
more likely to have been treated with azathioprine
(Pearson 2 = 25.68, P<0.001), mycophenolate (Pearson
2 = 9.70, P= 0.002) or rituximab (Pearson 2 = 3.98,
P= 0.046), but not cyclophosphamide. Hydroxychloroquine
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had been taken by 54.5% of the non-damage group
compared with 67.8% of the damage group with no
significant difference between both groups.
After multivariable analysis, including significant vari-
ables in the previous analysis plus age at the diagnosis
of SLE and ethnicity, only age at diagnosis of SLE (OR
1.04, P =0.014; 95% CI 1.00, 1.08), taking azathioprine
ever (OR 5.26, P =0.006; 95% CI 1.62, 17.1) kidney dis-
ease (OR 4.22; P =0.006; 95% CI 1.51, 11.76), CNS mani-
festations (OR 3.56, P =0.007; 95% CI 1.42, 8.95) and
positive anti-RNP antibody (OR 3.45 P =0.029; 95% CI
1.22, 9.8) remained statistically significant.
Time course of development of damage
For the whole group of 300 patients, the median follow-up
time from diagnosis was 160 months (range
12468 months). Of the 231 patients who developed
damage (SDI 5 1) the mean time to onset of damage
was 9.5 years (S.D. 6.97 years) from diagnosis of SLE.
SDI was measured at the first, fifth, 10th, 15th, 20th and
25th year after the diagnosis of SLE. The results are
shown in Table 2.
By year 1 of follow-up, 13% of patients already had
some damage but only 1.3% had SDI> 1. The proportion
of patients with SDI = 1 gradually increased to around one-
third at Year 10 and then remained stable. It seems likely
that this change occurred because the number of patients
developing new damage (i.e. SDI increases from 0 to 1)
was balanced by those moving into the SDI> 1 group.
The proportion in the SDI> 1 group increased more grad-
ually with time, until it reached about 30% at Year 15. It
should also be noted that there are a group of patients
TABLE 1 Comparison of characteristics of patients with and without damage
Damage (n=231, 77%) Non-damage (n=69, 23%) P-value
Age onset SLE, mean (S.D.) 31 (0.71) 30 (1.3) 0.389
Age F-U SLE, mean (S.D.) 40 (10.9) 39 (12.7) 0.494
Time to damage  in months, mean (S.D.) 114 (83.2) NA
Mean months F-U with no damage NA 328 (164.2)
Female, n (%) 217 (93.9) 63 (91.3) 0.441
Ethnicity, n (%)
Caucasian 148 (64.1) 45 (65.2) 0.484
Afro-Caribbean 59 (25.5) 20 (29)
Asian 24 (10.4) 4 (5.8)
Skin disease, n (%)
Rash 167 (72.3) 57 (82.6) 0.084
Photosensitivity 99 (42.9) 34 (49.3) 0.346
Alopecia 44 (19) 10 (14.5) 0.387
Mouth ulcers 59 (25.5) 15 (21.7) 0.520
Joint disease, n (%) 220 (95.2) 65 (94.2) 0.729
Kidney disease, n (%) 97 (42) 11 (15.9) <0.001
Serositis, n (%) 115 (49.8) 28 (40.6) 0.179
CNS disease, n (%) 70 (30.3) 10 (14.5) 0.009
Positive dsDNA, n (%) 148 (64.1) 33 (47.8) 0.016
Low complement (ever) 106 (45.88) 20 (23) 0.013
ENAs, n (%)
SM 27 (11.7) 7 (10.1) 0.723
Ro 79 (34.2) 21 (30.4) 0.561
La 30 (13) 8 (11.6) 0.760
RNP 63 (27.3) 9 (13) 0.015
RF 62 (26.9) 15 (21.7) 0.395
APS antibodies, n (%)
Positive 60 (26) 6 (9) 0.044
Treatment (ever), n (%)
Steroids (oral, i.v.) 176 (82.5) 34 (58.6) <0.001
HD steroids 121 (70.3) 27 (52.9) 0.001
Cyclophosphamide 35 (16.8) 5 (7.6) 0.064
Azathioprine 105 (50.5) 10 (15.2) <0.001
Mycophenolate 48 (23.1) 4 (6.1) 0.002
Rituximab 18 (8.9) 1 (1.5) 0.046
Hydroxycloroquine 141 (67.8) 36 (54.5) 0.050
Early use of HD steroids 103 (59.9) 25 (43.1) 0.026
Early use of IS 85 (49.7) 12 (20.7) <0.001
Numbers in bold are the ones with P-value < 0.05. F-U: follow-up; HD steroids: high dose of steroids; IS: immunosuppressants;
Lupus AC: lupus anticoagulant; NA: not applicable.
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who never develop any damage, even at 25 years follow-
up. The maximum damage score for any patient in the
cohort was 5.
Of the 231 patients who developed damage, 124 (53.7%)
did so by 5 years of follow-up and 107 (46.3%) at later times.
These groups are compared in Table 3. Univariable analysis
showed that the same factors that differed between damage
and no-damage groups also differed between the early
damage and late damage groups except that photosensitiv-
ity was more common in early damage than late damage,
whereas antiphospholipid and anti-RNP antibodies did not
differ between those groups. In multivariable analysis, how-
ever, there were no significant differences between the early
damage and late damage groups.
We used Kaplan-Meier analysis to compare the rates of
developing damage in groups stratified according to fac-
tors that applied from the beginning of the follow-up
period. These were time to damage, ethnicity, early use
of high-dose steroids and early use of IS. Kaplan-Meier
curves are shown in Fig. 1(ad).
Ethnicity was a risk factor for developing chronic
damage (HR 1.22 for African/Caribbean patients com-
pared with white patients, P =0.045; 95% CI 1.00, 1.50)
but there was no risk associated with gender or age at
diagnosis of SLE (HR 0.79, P =0.402; 95% CI 0.46, 1.36;
HR 1.00, P =0.932; 95% CI 0.99, 1.01).
With regard to the treatment, taking early high dose of
steroids and early use of IS were both risk factors for de-
veloping damage (HR 1.47, P =0.014; 95% CI 1.08, 1.99;
HR 2.08, P <0.001; 95% CI 1.53, 2.82).
Mortality
Overall, 87/300 patients died during the follow-up period.
More than a third of the patients (81/231 = 35%) with
damage died during their follow-up, whereas only 6/69
(8.7%) patients died in the non-damage group.
Conversely 93.1% of patients who died had damage com-
pared with 70.4% of those who survived (P <0.001).
Sepsis was the main cause of death (26.4%), followed
by cancer (25.3%), cardiovascular events (19.5%), multi-
organ failure due to SLE (14.9%) and others (9.2%). There
were four patients with unknown cause of death. Table 4
shows the characteristics of the patients who died com-
pared with those who survived to the end of the follow-up
period. Patients who died were older at the time of diag-
nosis of SLE (33.6 years; S.D. ± 12.03 vs 29.4 years; S.D. ±
9.77, P =0.0006). There were differences among some
clinical manifestations between the two groups: CNS dis-
ease (Pearson 2 5.04, P =0.025), serositis (Pearson
2 4.72, P =0.030) and alopecia (Pearson 2 5.91,
P =0.015) were more common in those who died.
With regard to treatment, patients who died were sig-
nificantly more likely to have ever taken oral or i.v. steroids
(Pearson 2 9.0, P =0.003), to have had high dose of ster-
oids (Pearson 2 15.34, P <0.001), early high dose of ster-
oids (Pearson 2 8.14, P =0.004) and azathioprine
(Pearson 2 16.45, P <0.001).
We carried out multivariable analysis, including signifi-
cant variables in the previous analysis plus age and eth-
nicity. Age of onset of SLE (OR 1.08, P <0.001; 95% CI
1.04, 1.12), having damage (OR 4.08, P =0.025; 95% CI
1.19, 14.01), positive antiphospholipid antibodies (OR
3.45, P =0.002; 95% CI 1.57, 7.62), serositis (OR 2.22,
P =0.030; 95% CI 1.04, 4.77), and treatment with
azathioprine (OR 2.83, P =0.013; 95% CI 1.24, 6.45), re-
mained statistically significant as factors differentiating
patients who died from those who survived.
Survival analysis
Figure 2 shows Kaplan-Meier curves analysing factors
associated with earlier death in this cohort. The presence
of any damage (Fig. 2a) was associated with increased
mortality (HR 8.43, P <0.001; 95% CI 2.64, 26.9).
Age at diagnosis, sex, ethnicity, early use of high-dose
steroids and early use of IS were analysed. Age at diag-
nosis (HR 1.04, P =0.001; 95% CI 1.02, 1.06) and early use
of high dose of steroids (HR 2.48, P =0.003; 95% CI 1.35,
4.53) were associated with death. Early IS treatment was
not significantly associated with death (HR 1.7, P =0.057;
95% CI 0.98, 2.98). After the multivariable analysis, early
high dose of steroids remained statistically significant (HR
2.85, P =0.001; 95% CI 1.52, 5.34).
Discussion
In our multi-time-point Kaplan-Meier analysis of a well
characterized, multi-ethnic SLE cohort followed for up to
40 years we found development of damage to be strongly
associated with increased mortality and identified risk-
factors for developing damage in these patients. A
number of studies over the last 20 years have investigated
factors associated with development of damage in
TABLE 2 Distribution of chronic damage in SLE patients
Time(years)
Patients under
follow-up SDI =0 n (%) SDI = 1 n (%) SDI> 1 n (%)
Median damage
score (range)
Deceased
patients
First 300 261 (87) 35 (11.7) 4 (1.3) 0 (02) 0 (0)
Fifth 295 177 (60) 84 (28.5) 34 (11.5) 0 (03) 5 (1.7)
10th 271 121 (44.6) 92 (33.9) 58 (21.4) 1 (04) 8 (2.7)
15th 224 79 (35.3) 80 (35.7) 65 (29.01) 1 (05) 8 (2.8)
20th 157 34 (21.7) 66 (42) 57 (36.3) 1 (05) 11 (3.9)
25th 105 15 (14.3) 44 (41.9) 46 (43.8) 1 (05) 55 (20.5)
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patients with SLE. These include single-centre [2, 6,
1018] and multicentre [8, 1925] studies. The reports
vary widely in the ethnic composition of the study popu-
lation, the number of patients and length of follow-up.
Some are cross-sectional with SDI measured at a single
time point [2, 6, 12, 15, 21, 25] whereas others describe
longitudinal SDI data often reported at one-year or five-
year time points [16, 18]. Very few reports have used
Kaplan-Meier analysis to analyse development of
damage (as opposed to mortality) over time [24, 26].
As described by Sutton et al. in a systematic literature
review of 2013 [4], authors have consistently agreed that
increasing age and disease duration are associated with
increased SDI. This finding is not surprising given the fact
that, by definition, damage is irreversible and the SDI can
only increase. For other factors, however, findings are in-
consistent between different reports. In some cases, this
is because the populations studied do not allow assess-
ment of the effects of particular factors; for example, eth-
nicity in predominantly monoethnic cohorts [2, 6, 8, 15,
16, 21, 22] or effect of hydroxychloroquine where very
few patients are not taking this drug [6, 15]. No previous
studies have been able to provide Kaplan-Meier curves for
development of damage over 30+ years follow-up, as we
have done here. The only studies with similar length of
follow-up are from Niigata, Japan [2] and Brescia, Italy
[16], both in populations dominated by a single ethnicity.
In contrast we report long-term follow-up, including
Kaplan-Meier analysis of damage accrual, in a multi-
ethnic population.
TABLE 3 Comparison of characteristics of patients with and without early damage
Early damage (n=124, 53.7%) Late damage (n=107, 46.3%) P-value
Age onset SLE, mean (S.D.) 30 (10.8) 31 (10.8) 0.250
Age F-U SLE, mean (S.D.) 38 (10.5) 42 (11.1) 0.028
Female, n (%) 117 (94.4) 100 (93.5) 0.081
Ethnicity, n (%)
Caucasian 71 (57.3) 77 (72)
Afro-Caribbean 37 (29.8) 22 (20.6) 0.064
Asian 16 (12.9) 8 (7.5)
Skin disease, n (%)
Rash 96 (77.4) 71 (66.4) 0.061
Photosensitivity 63 (50.8) 36 (33.6) 0.009
Alopecia 27 (21.8) 17 (15.9) 0.256
Mouth ulcers 33 (26.6) 26 (19.6) 0.688
Joint disease, n (%) 117 (94.3) 103 (96.3) 0.497
Kidney disease, n (%) 63 (50.8) 34 (31.8) 0.003
Serositis, n (%) 59 (47.6) 56(52.3) 0.471
CNS disease, n (%) 46 (37.1) 24 (22.4) 0.016
Positive dsDNA, n (%) 87 (70.2) 61 (57) 0.038
Low complement (ever) 65 (52.4) 41 (38.3) 0.032
ENAs, n (%)
Sm 14 (11.3) 13 (12.1) 0.839
Ro 45 (36.3) 34 (31.8) 0.471
La 17 (13.7) 13 (12.1) 0.725
RNP 33 (26.2) 30 (28) 0.808
RF 29 (23.4) 33 (30.8) 0.202
APS antibodies, n (%)
Positive 33 (26.6) 27 (25.2) 0.570
Treatment (ever), n (%)
Steroids (oral, i.v.) 86 (69.4) 56 (52.3) 0.002
HD steroids 75 (60.5) 46 (43) 0.006
Cyclophosphamide 24 (19.4) 11 (10.3) 0.121
Azathioprine 62 (50) 43 (40.2) 0.496
Mycophenolate 31 (25) 17 (15.9) 0.176
Rituximab 11 (8.9) 7 (6.5) 0.681
Hydroxycloroquine 80 (64.5) 61 (57) 0.998
Early use of HD steroids 65 (52.4) 38 (35.5) 0.011
Early use of IS 55 (44.4) 30 (28) 0.017
Death, n (%) 42 (33.9) 39 (36.4) 0.682
Numbers in bold are the ones with P-value < 0.05. F-U: follow-up; HD steroids: high dose of steroids; IS: immunosuppressants;
Lupus AC: lupus anticoagulant.
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Those groups who reported on ethnicity generally found
that Afro-Caribbean and Hispanic patients develop more
damage than Caucasians [4, 14, 19, 24]. Shaharir et al. in
Malaysia also showed that patients of Indian ethnicity had
more damage than Chinese or Malays [12]. However, Petri
et al. found that the association between Afro-Caribbean
ethnicity and damage disappeared on multivariable ana-
lysis and concluded that it was confounded by other fac-
tors, such as income, hypertension and proteinuria [14].
The curve in Fig. 1b shows that Afro-Caribbean patients in
our study do develop more damage than other groups,
and the divergence in curves starts early in the disease
course. However, this finding is not confirmed by signifi-
cant P-values between ethnic groups in Table 1 or by
multivariable analysis, suggesting that ethnicity may be a
surrogate for other factors as suggested by Petri [14].
Similarly, Geraldino-Pardilla et al. found considerable dif-
ferences in disease outcomes and damage between two
groups of Dominican patients; one in New York City and
the other in the Dominican Republic, suggesting that
Dominican ethnicity was not the main factor influencing
damage [21].
Our study includes only 20 men, which means that we
are unable to comment regarding any association of
damage with gender (Table 1). Some larger studies have
reported that men accrue damage faster than women [24,
27].
Most groups that have measured SDI at various time
intervals report a linear increase in the number of patients
with damage and the median SDI [4, 15, 16, 18, 24]. An
exception is the paper of Nossent et al. [25] from a multi-
centre European cohort, where they suggested that SDI
reaches a plateau. It has, however, been argued that this
finding could be due to a healthy survivor effect, whereby
the patients who would have continued to develop
damage died before 20 years of follow-up. In our current
study, Fig. 1a supports the idea of linear accumulation of
damage with time, with no plateau being seen.
Similar to our findings, other groups have reported an
association between damage and CNS involvement [4, 8,
11, 12, 25] or renal disease [2, 4, 15, 17, 25, 28, 29]. Our
findings of more damage in patients with elevated anti-
dsDNA and reduced complement are also consistent
with some reports [2, 1214, 25] though others found no
such link [16, 24]. However, although Prasad et al. [13]
found that anti-SM positivity was associated with
increased development of damage, ours is the
first study to report an association between positive
FIG. 1 Kaplan-Meier analysis of development of damage in whole population and groups stratified by ethnicity or early
therapy
(a) Time to damage; (b) ethnicity and damage; (c) early high dose of steroids and damage; (d) early IS and damage.
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anti-RNP antibody and damage. In contrast, the associ-
ation between antiphospholipid-positivity and damage
has been established by many authors [2, 4, 12, 14] and
our results support this conclusion.
The association between use of steroids and damage
has been widely evaluated in previous reports [46, 10,
1418, 2225, 27, 30]. The relationship is complex be-
cause, whereas these drugs can cause effects such as
cataract and avascular necrosis, under-use of steroids in
patients with active disease could also lead to damage
such as renal failure. Use of steroids has been recorded
in different ways, such as ever-use, cumulative dose and
average daily dose. The majority of studies have shown
that steroids are associated with higher SDI and Al-Sawah
et al. pointed out that even a reduction of 1 mg per day in
average dose could potentially reduce damage [10].
Conti, et al. [6] found a strong correlation between
glucocorticoids and damage. Gladman and colleagues
[31] also attributed the presence of damage to the use
of steroids, particularly later in the disease course. Data
from the Lupus in Minorities: Nature vs Nurture (LUMINA)
cohort suggested an association between daily use of
glucocorticoids and a shorter time to damage develop-
ment [23, 27]. A far smaller number of studies did not
find a relation between damage and use of steroids,
including a very large Japanese study which, similar to
ours, included SDI data from 293 patients with up to
40 years follow-up [15].
Data on association of IS use with damage accrual are
less extensive, as not all papers report on these drugs and
different authors have looked at different drugs. Sutton et
al. in their literature review described associations be-
tween damage accrual and use of cyclophosphamide or
azathioprine though pointing out the possibility of
TABLE 4 Differences between deceased and alive patients
Deceased (n=87) Alive (n=213) P-value
Age onset SLE, mean (S.D.) 34 (12.8) 29 (9.7) 0.0006
Time to death in months median (IQR) 158 (115) NA
SDI>0, n (%) 81 (93.1) 150 (70.4) <0.001
Female, n (%) 85 (97.7) 195 (91.5) 0.053
Ethnicity
Caucasian 54 (62.1) 139 (65.3) 0.859
Afro-Caribbean 24 (27.6) 55 (25.8)
Asian 9 (10.3) 19 (8.9)
Skin disease, n (%)
Rash 64 (73.5) 160 (75.1) 0.779
Photosensitivity 35 (40.2) 98 (46) 0.361
Alopecia 23 (26.4) 31 (14.6) 0.015
Mouth ulcers 25 (28.7) 49 (23) 0.296
Joint disease, n (%) 83 (95.4) 202 (94.8) 0.838
Kidney disease, n (%) 29 (33.3) 79 (37.1) 0.539
Serositis, n (%) 50 (57.5) 93 (43.7) 0.030
CNS disease, n (%) 31 (35.6) 49 (23) 0.025
Positive dsDNA 56 (64.4) 125 (58.7) 0.361
Low complement (ever) 41 (47.1) 85 (39.9) 0.250
ENAs, n (%)
SM 9 (11.1) 25 (11.7) 0.730
Ro 26 (32.1) 74 (34.7) 0.418
La 12 (14.8) 26 (12.2) 0.708
RNP 21 (24.1) 51 (23.9) 0.971
RF 24 (27.6) 53 (24.9) 0.627
APS antibodies
Positive 28 (32.2) 41 (19.2) 0.005
Treatment (ever), n (%)
Steroids (oral, i.v.) 68 (78.2) 108 (50.7) 0.003
HD steroids 63 (72.4) 85 (39.9) <0.001
Cyclophosphamide 17 (21.5) 23 (10.8) 0.089
Azathioprine 51(58.6) 64 (30.05) <0.001
Mycophenolate 19 (21.8) 33 (15.5) 0.371
Rituximab 7 (8) 12 (5.6) 0.578
Hydroxycloroquine 49 (56.3) 128 (23) 0.107
Early use of HD steroids 53 (60.9) 75 (35.2) 0.004
Early use of IS 36 (41.4) 61 (28.6) 0.338
Numbers in bold are the ones with P-value < 0.05. F-U: follow-up; HD steroids: high dose of steroids; IS: immunosuppressants;
Lupus AC: lupus anticoagulant; NA: not applicable.
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confounding by indication (i.e. only those with more
severe disease receive these drugs) [4]. Petri et al. [14]
and Nossent et al. [25] found an association with cyclo-
phosphamide but not azathioprine.
In our study, both steroids and some IS (azathioprine,
mycophenolate and rituximab but not cyclophosphamide)
were associated with damage in the univariate analysis
but not in the multivariable analysis. A possible explan-
ation for these findings is due to collinearity of steroid and
IS dose so that neither can be shown to exert an inde-
pendent effect. In an effort to determine the role of therapy
decisions taken early in the course of disease, we carried
out Kaplan-Meier analysis comparing patients who
received high-dose steroids or IS within the first two
years of follow-up with those who did not. Figure 1c and
d clearly show that patients who receive these treatments
early in the disease course develop more damage over
time and that the curves remain separate throughout the
follow-up period.
In contrast to several previous authors [4, 10, 12, 14, 24]
we found no convincing evidence that use of hydroxy-
chloroquine protects against damage development. The
major causes of death in our patient group were sepsis,
cancer, cardaiovascular events and SLE disease activity
which is similar to the results of previous groups [2, 15,
16]. Both Kaplan-Meier analysis (Fig. 2a) and multivariable
analysis confirmed the strong association between pres-
ence of damage and increased risk of death that has been
established in other groups. Early high-dose steroids, but
not early IS were associated with increased mortality.
A limitation of our analysis was the absence of data on
disease activity. The association of active disease with
damage accrual had already been established in this
same group of patients by Lopez et al. [9] and we did
not have activity data covering the whole follow-up
period. However, low complement, elevated anti-dsDNA
and presence of renal or CNS involvement are all markers
of more active disease and all were associated with
increased damage. It would also have been interesting
to look at individual items of damage to investigate
whether particular organs are affected by damage earlier
than others. This was beyond the scope of the current
analysis.
In conclusion, this study is the first report of damage
accrual and mortality in a large multi-ethnic cohort of pa-
tients with SLE followed for up to 40 years and underlines
the importance of preventing or minimizing damage as far
as possible, given the strong link between damage and
FIG. 2 Kaplan-Meier analysis of mortality in whole population and groups stratified by presence of damage or by early
therapy
(a) Time to death; (b) early high dose of steroids and death; (c) early IS and death.
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mortality. Patients who receive high-dose steroids and IS
early in the disease course are a group with poorer out-
comes as regards damage and mortality. However, it is
not clear whether this finding is primarily because of ad-
verse effects of the drugs or because these patients have
severe disease from the beginning, requiring increased
use of those agents to ameliorate disease. A move to
treatment of severe SLE using less toxic drugs may
begin to resolve this conundrum as well as achieving
better outcomes for patients.
Funding: No specific funding was received from any fund-
ing bodies in the public, commercial or not-for-profit sec-
tors to carry out the work described in this manuscript.
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